Patents by Inventor Pierre Meulien

Pierre Meulien has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Cell lines from a transgenic mouse which express biologically active IX factor
    Patent number: 5814716
    Abstract: Cell lines have been prepared from transgenic mice comprised of a first exogenous DNA sequence encoding human factor IX which is controlled by a promoter region specific for hepatic cells and a second exogenous DNA sequence encoding an oncogene, such as the SV40 virus gene encoding the T-antigen or the mouse c-myc gene, which is controlled by a promoter region specific for hepatic cells. Promoter regions specific for hepatic cells included the promoter region for the factor IX gene and the promoter region for the .alpha.-1 antitrypsin gene. The cultured cells produce biologically active human factor IX which is then isolated from the culture media.
    Type: Grant
    Filed: February 24, 1995
    Date of Patent: September 29, 1998
    Assignee: Transgene S.A.
    Inventors: Sophie Jallat, Pierre Meulien, Andrea Pavirani, Frederic Perraud
  • DNA sequence coding for human factor IX or a similar protein, expression vector, transformed cells, method for preparing factor IX and corresponding products obtained
    Patent number: 5521070
    Abstract: The present invention relates to a novel DNA sequence coding for factor IX or a similar protein, corresponding to a prosequence and to mature factor IX or the mature similar protein. According to the invention, position (-3) in the prosequence is occupied by a codon coding for valine, arginine, lysine, threonine or serine, and/or the first codon of the sequence coding for the mature protein codes for an alanine.
    Type: Grant
    Filed: March 14, 1994
    Date of Patent: May 28, 1996
    Assignee: Transgene S.A.
    Inventor: Pierre Meulien
  • Factor VIII analog, preparation process, and pharmaceutical composition containing it
    Patent number: 5112950
    Abstract: Factor VIII analog which has undergone deletion of amino acids 771 to 1666, prepared from eukaryotic cells transformed by an expression vector carrying the cDNA of the factor VIII which has undergone deletion.
    Type: Grant
    Filed: June 26, 1991
    Date of Patent: May 12, 1992
    Assignee: Transgene S.A.
    Inventors: Pierre Meulien, Andrea Pavirani